Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Amplify Weight Loss Drug & Treatment ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Amplify Weight Loss Drug & Treatment ETF (THNR) has returned -2.52% so far this year and 15.99% over the past 12 months.
Amplify Weight Loss Drug & Treatment ETF
- 1D
- 3.13%
- 1M
- -5.29%
- YTD
- -2.52%
- 6M
- 6.73%
- 1Y
- 15.99%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since May 21, 2024, THNR's average daily return is +0.01%, while the average monthly return is +0.07%. At this rate, your investment would double in approximately 82.5 years.
Historically, 52% of months were positive and 48% were negative. The best month was Nov 2025 with a return of +11.6%, while the worst month was Mar 2025 at -8.3%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 4 months.
On a daily basis, THNR closed higher 52% of trading days. The best single day was Apr 9, 2025 with a return of +5.2%, while the worst single day was Apr 4, 2025 at -6.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.90% | -0.93% | -5.29% | -2.52% | |||||||||
| 2025 | 2.57% | 1.51% | -8.27% | 2.26% | 1.03% | 2.02% | -1.11% | 2.12% | 2.10% | -0.46% | 11.62% | -1.46% | 13.65% |
| 2024 | -0.26% | 2.90% | 1.03% | 7.05% | -4.94% | -5.64% | -5.03% | -5.22% | -10.36% |
Benchmark Metrics
Amplify Weight Loss Drug & Treatment ETF has an annualized alpha of -6.55%, beta of 0.66, and R² of 0.32 versus S&P 500 Index. Calculated based on daily prices since May 22, 2024.
- This ETF participated in 125.23% of S&P 500 Index downside but only 56.01% of its upside — more exposed to losses than it benefited from rallies.
- Beta of 0.66 may look defensive, but with R² of 0.32 this ETF is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this ETF's risk.
- R² of 0.32 means the benchmark explains less than half of this ETF's behavior — treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- -6.55%
- Beta
- 0.66
- R²
- 0.32
- Upside Capture
- 56.01%
- Downside Capture
- 125.23%
Expense Ratio
THNR has an expense ratio of 0.59%, placing it in the medium range.
Return for Risk
Risk / Return Rank
THNR ranks 39 for risk / return — below 39% of ETFs on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Amplify Weight Loss Drug & Treatment ETF (THNR) and compare them to a chosen benchmark (S&P 500 Index).
| THNR | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.73 | 0.90 | -0.17 |
Sortino ratioReturn per unit of downside risk | 1.14 | 1.39 | -0.24 |
Omega ratioGain probability vs. loss probability | 1.14 | 1.21 | -0.07 |
Calmar ratioReturn relative to maximum drawdown | 1.27 | 1.40 | -0.13 |
Martin ratioReturn relative to average drawdown | 3.45 | 6.61 | -3.16 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore THNR risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Amplify Weight Loss Drug & Treatment ETF provided a 1.68% dividend yield over the last twelve months, with an annual payout of $0.41 per share.
| Period | TTM | 2025 | 2024 |
|---|---|---|---|
| Dividend | $0.41 | $0.41 | $0.22 |
Dividend yield | 1.68% | 1.64% | 0.98% |
Monthly Dividends
The table displays the monthly dividend distributions for Amplify Weight Loss Drug & Treatment ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.41 | $0.41 |
| 2024 | $0.22 | $0.22 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Amplify Weight Loss Drug & Treatment ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Amplify Weight Loss Drug & Treatment ETF was 32.51%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Amplify Weight Loss Drug & Treatment ETF drawdown is 10.54%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -32.51% | Sep 3, 2024 | 150 | Apr 8, 2025 | — | — | — |
| -6.89% | Jul 15, 2024 | 18 | Aug 7, 2024 | 6 | Aug 15, 2024 | 24 |
| -1.81% | May 22, 2024 | 5 | May 29, 2024 | 3 | Jun 3, 2024 | 8 |
| -1.57% | Jun 26, 2024 | 6 | Jul 3, 2024 | 4 | Jul 10, 2024 | 10 |
| -1.1% | Jun 11, 2024 | 6 | Jun 18, 2024 | 3 | Jun 24, 2024 | 9 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...